Gilead’s Kite Pharma gets FDA nod for second CAR-T cell therapy July 24, 2020 Auto Bot BioPharma, biopharma nl, California, CAR-T, cell therapy, Foster City, Gilead Sciences, Tecartus 0 The agency approved Tecartus, previously developed under the name KTE-X19, as the first CAR-T therapy for mantle cell lymphoma. The company had previously won approval for another CAR-T, Yescarta, in 2017, for diffuse large B-cell lymphoma.